This study is a single treatment period, single dose gamma scintigraphy study investigating
the deposition in the lungs of a Budesonide, Glycopyrronium and Formoterol Fumarate Metered
Dose Inhaler (BGF-MDI). This study will be investigating how the drug (known as PT010) is
distributed in the lungs of Chronic Obstructive Pulmonary Disease (COPD) patients (with
moderate to very severe COPD) following a maximal 10 second breath hold. This inhaler is
intended to be used in the treatment of COPD, which is a group of diseases which cause lung
problems and difficulty breathing. PT010 is a new combination product of 3 marketed drugs
called Glycopyrronium, Formoterol Fumarate and Budesonide.